Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Sivahari P, Gorantla"'
Autor:
Vijay Kumar Boddu, Piet Zamzow, Mario Wolfgang Kramer, Axel S. Merseburger, Sivahari Prasad Gorantla, Matthias Klinger, Lena Cramer, Thorben Sauer, Timo Gemoll, Nikolas von Bubnoff, Frank Gieseler, Masoud Darabi
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Extracellular vesicles (EVs), including microvesicles, hold promise for the management of bladder urothelial carcinoma (BLCA), particularly because of their utility in identifying therapeutic targets and their diagnostic potential
Externí odkaz:
https://doaj.org/article/27968117661440eb98397edea6f0a8e7
Autor:
Sivahari Prasad Gorantla, Tony Andreas Mueller, Corinna Albers‐Leischner, Martina Rudelius, Nikolas vonBubnoff, Justus Duyster
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 415-430 (2024)
Tyrosine‐protein kinase (janus kinase; JAK)–signal transducer and activator of transcription (STAT) signaling plays a pivotal role in the development of myeloproliferative neoplasms (MPNs). Treatment with the potent JAK1/JAK2‐specific inhibitor
Externí odkaz:
https://doaj.org/article/7d73443b165c4267b410f643f968e47e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Leukemia represents a diverse group of hematopoietic neoplasms that can be classified into different subtypes based on the molecular aberration in the affected cell population. Identification of these molecular classification is required to identify
Externí odkaz:
https://doaj.org/article/64383139e03d4219955c2de6cea5ea30
Autor:
Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis. Ruxolitinib will remain a main stay in the treatment of MPN patients due to its effective the
Externí odkaz:
https://doaj.org/article/d15f0a582d1444fa955de4dbeaac8a8c
Autor:
Stefanie Kreutmair, Lena Johanna Lippert, Cathrin Klingeberg, Corinna Albers-Leischner, Salome Yacob, Valeria Shlyakhto, Tony Mueller, Alina Mueller-Rudorf, Chuanjiang Yu, Sivahari Prasad Gorantla, Cornelius Miething, Justus Duyster, Anna Lena Illert
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The NPM-ALK fusion kinase is expressed in 60% of systemic anaplastic large-cell lymphomas (ALCL). A Nuclear Interaction Partner of ALK (NIPA) was identified as a binding partner of NPM-ALK. To identify the precise role of NIPA for NPM-ALK-driven lymp
Externí odkaz:
https://doaj.org/article/10e48b350181413cbc7c7d67f9d23de4
Autor:
Rüdiger Braun, Olha Lapshyna, Jessica Watzelt, Maren Drenckhan, Axel Künstner, Benedikt Färber, Ahmed Ahmed Mohammed Hael, Louisa Bolm, Kim Christin Honselmann, Björn Konukiewitz, Darko Castven, Malte Spielmann, Sivahari Prasad Gorantla, Hauke Busch, Jens-Uwe Marquardt, Tobias Keck, Ulrich Friedrich Wellner, Hendrik Ungefroren
Publikováno v:
Cells, Vol 12, Iss 4, p 587 (2023)
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is exceedingly poor. Although surgical resection is the only curative treatment option, multimodal treatment is of the utmost importance, as only about 20% of tumors are primarily resectable at
Externí odkaz:
https://doaj.org/article/217dd6f9a824404c944446bfa3c6760d
Autor:
Chuanjiang Yu, Sivahari P. Gorantla, Alina Müller-Rudorf, Tony A. Müller, Stefanie Kreutmair, Corinna Albers, Lena Jakob, Lena J. Lippert, Zhenyu Yue, Monika Engelhardt, Marie Follo, Robert Zeiser, Tobias B. Huber, Justus Duyster, Anna L. Illert
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
Autophagy is a genetically regulated process of adaptation to metabolic stress and was recently shown to be involved in the treatment response of chronic myeloid leukemia (CML). However, in vivo data are limited and the molecular mechanism of autopha
Externí odkaz:
https://doaj.org/article/43f9cde6ec7e475f9adbfda9b0c7265e
Autor:
Philip Keye, Anne Charlet, Michael Reth, Kathrin Kläsener, Max Kappenstein, Cornelia Endres, Teresa Poggio, Nikolas von Bubnoff, Anna Lena Illert, Jana Sänger, Stefanie Kreutmair, Cornelius Miething, Christoph Rummelt, Justus Duyster, Sivahari P. Gorantla
Publikováno v:
Leukemia. 36:701-711
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. W
Autor:
Christoph Rummelt, Justus Duyster, Florian H Heidel, Anne Charlet, Konstanze Döhner, Thomas Fischer, Nikolas von Bubnoff, Sivahari P. Gorantla, Cornelia Endres, Manja Meggendorfer, Torsten Haferlach
Publikováno v:
Leukemia. 35:2017-2029
An important limitation of FLT3 tyrosine kinase inhibitors (TKIs) in FLT3-ITD positive AML is the development of resistance. To better understand resistance to FLT3 inhibition, we examined FLT3-ITD positive cell lines which had acquired resistance to
Autor:
Anne, Charlet, Max, Kappenstein, Philip, Keye, Kathrin, Kläsener, Cornelia, Endres, Teresa, Poggio, Sivahari P, Gorantla, Stefanie, Kreutmair, Jana, Sänger, Anna L, Illert, Cornelius, Miething, Michael, Reth, Justus, Duyster, Christoph, Rummelt, Nikolas, von Bubnoff
Publikováno v:
Leukemia. 36(3)
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. W